{
    "paper_id": "09da1f7c0df0de6af2cd76fbe05ea83fcac3b673",
    "metadata": {
        "title": "",
        "authors": [
            {
                "first": "Jens",
                "middle": [],
                "last": "Vikse",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Brandon",
                "middle": [
                    "Michael"
                ],
                "last": "Henry",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Tocilizumab is primarily used for rheumatological conditions, including rheumatoid arthritis and giant cell arteritis. Rheumatologists have extensive experience using tocilizumab; however, this may not be the case for intensivists, infectious disease specialists, and other physicians treating critically ill COVID-19 patients. Therefore, we would like to highlight a rare but feared complication of tocilizumab: intestinal perforation [2] . The mechanism for intestinal perforation in patients receiving tocilizumab is not fully understood, but prior diverticulitis has been noted as a risk factor [2] .",
            "cite_spans": [
                {
                    "start": 1011,
                    "end": 1014,
                    "text": "[2]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1174,
                    "end": 1177,
                    "text": "[2]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "The human host receptor of SARS-CoV-2 is angiotensin-converting enzyme 2 (ACE2), which is highly expressed in the intestines [3] . Intestinal viral replication is likely considering the ACE2 expression, gastrointestinal symptoms and presence of SARS-CoV-2 RNA in fecal samples [4, 5] . Some gastrointestinal symptoms, such as abdominal pain, are associated with increased disease severity [5] .",
            "cite_spans": [
                {
                    "start": 125,
                    "end": 128,
                    "text": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 277,
                    "end": 280,
                    "text": "[4,",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 281,
                    "end": 283,
                    "text": "5]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 389,
                    "end": 392,
                    "text": "[5]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Furthermore, critically ill COVID-19 patients may have altered hemodynamics, potentially leading to intestinal hypoperfusion that can compromise intestinal mucosal integrity. More studies are required to evaluate whether these variables influence the risk of intestinal perforation with tocilizumab in critical COVID-19 cases; however, clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevation and may initially go unnoticed in sedated and ventilated patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Funding: None",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declarations"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J-W",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "G-Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Int J Antimicrob Agents",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Strangfeld",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Richter",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Siegmund",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Herzer",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rockwitz",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Demary",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ann Rheum Dis",
            "volume": "76",
            "issn": "",
            "pages": "504--514",
            "other_ids": {
                "DOI": [
                    "10.1136/annrheumdis-2016-209773"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Dan",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Oral Sci",
            "volume": "12",
            "issn": "",
            "pages": "1--5",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Gut",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1136/gutjnl-2020-321013"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Henry",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Olivera",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Benoit",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lippi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Intern Emerg Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1007/s11739-020-02329-9"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway 2. Cardiac Intensive Care Unit, Cincinnati Children's Hospital Medical Center, Ohio, USA Correspondence to: Brandon Michael Henry, M.D. Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH, USA 45229, brandon.henry@cchmc.al. [1] discussed the use of tocilizumab, a monoclonal anti-IL-6 receptor antibody, in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown.",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": [
        {
            "text": "Ethical Approval: NA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Competing Interests: None"
        }
    ]
}